Compare · LYRA vs MDLN
LYRA vs MDLN
Side-by-side comparison of Lyra Therapeutics Inc. (LYRA) and Medline Inc. (MDLN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LYRA and MDLN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $50.91B, about 1118.4x LYRA ($45.5M).
- Over the past year, LYRA is down 93.9% and MDLN is down 4.8% - MDLN leads by 89.1 points.
- MDLN has hit the wire 4 times in the past 4 weeks while LYRA has been quiet.
- MDLN has more recent analyst coverage (25 ratings vs 7 for LYRA).
- Company
- Lyra Therapeutics Inc.
- Medline Inc.
- Price
- $0.49-61.33%
- $38.78+3.02%
- Market cap
- $45.5M
- $50.91B
- 1M return
- +0.00%
- +7.57%
- 1Y return
- -93.89%
- -4.83%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- 2025
- News (4w)
- 0
- 4
- Recent ratings
- 7
- 25
Lyra Therapeutics Inc.
Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The company's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. Its product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
Latest LYRA
- Director Smith W Bradford returned 640 shares to the company, closing all direct ownership in the company (SEC Form 4)
- SEC Form 15-12G filed by Lyra Therapeutics Inc.
- SEC Form 25 filed by Lyra Therapeutics Inc.
- SEC Form 8-K filed by Lyra Therapeutics Inc.
- Lyra Therapeutics, Inc. Announces Intention to Voluntarily File Form 25 for Delisting from Nasdaq and Subsequent Deregistration with the SEC
- SEC Form 8-K filed by Lyra Therapeutics Inc.
- SEC Form 4 filed by Palasis Maria
- SEC Form 4 filed by Cavalier Jason
- SEC Form 10-K filed by Lyra Therapeutics Inc.
- SEC Form EFFECT filed by Lyra Therapeutics Inc.
Latest MDLN
- Medline strengthens California distribution network with new 1 million-square-foot facility in Perris
- Medline Inc. filed SEC Form 8-K: Leadership Update
- Medline announces Prime Vendor agreement with Allina Health
- Securing new 1.6-plus million square feet of new space after fire, Medline leases two large distribution centers in Northern California
- Medline to report second quarter 2026 results on August 5, 2026
- Officer Abrams William J covered exercise/tax liability with 1,308 shares, decreasing direct ownership by 7% to 16,546 units (SEC Form 4)
- Chief Human Resources Officer Shryock Christopher P covered exercise/tax liability with 872 shares, decreasing direct ownership by 7% to 11,031 units (SEC Form 4)
- Chief Operating Officer Miller Stephen L covered exercise/tax liability with 1,889 shares, decreasing direct ownership by 7% to 23,899 units (SEC Form 4)
- Chief Legal Officer Liberman Alexander M. covered exercise/tax liability with 872 shares, decreasing direct ownership by 7% to 11,031 units (SEC Form 4)
- Chief Product Officer Laabs Amanda H. covered exercise/tax liability with 1,889 shares, decreasing direct ownership by 7% to 23,899 units (SEC Form 4)